Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$62.90M$62.90M+69.6% vs Q3 2023 Net Income-$54.81M-$54.81MN/M vs Q3 2023 EPS Diluted-$0.70-$0.70N/M vs Q3 2023 Operating Income-$56,149,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$42,507,000N/M Margins · derivedOperating margin-89.3%+160.3 pt vs Q3 2023
Net margin-87.1%
ended Sep 30, 2024 · filed Oct 31, 2024 · 31 d after period end